ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Cancer survivors' acceptability and perspectives on engagement with digital cognitive-behavioral therapy for insomnia: a mixed methods perspective.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of eHealth interventions in long-term follow-up care for breast and gynecological cancer survivors: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Bibliometric and visual analysis of cancer-related insomnia research from 2015 to 2025.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeInsomnia is one of the most prevalent, persistent, and impairing conditions for which cancer survivors want treatment. However, the evidence-based first-line treatment, cognitive-behavioral therapy for insomnia (CBT-I), is seldom available to cancer survivors. Digital CBT-I improves dissemination, but its impact depends on patients' acceptance and preferences. We aimed to determine the acceptability of and explore perspectives of digital CBT-I for cancer survivors.
methodsResponses collected at study exit by 123 cancer survivors (mean age 47.1 years, 95.9% women, 76.4% breast cancer) who completed a digital CBT-I, OncoSleep, were analyzed using mixed methods. The exit survey included quantitative measures of acceptability, and qualitative insights were gathered through a free-response item. Responses were systematically coded and analyzed using deductive and inductive approaches to identify recurrent themes.
resultsThe digital CBT-I, OncoSleep, received high ratings for perceived efficacy, satisfaction, helpfulness, usability, likelihood of future use of therapeutic techniques, likelihood of recommendation, and user experience. Patients who showed clinically significant improvements in insomnia severity reported better user experience. Analyses revealed eight themes were relevant for engagement with treatment: clinician support and monitoring, interactive features and ease of use, perceived efficacy of treatment techniques, convenience and non-hospital setting, validation of unmet needs, sleep medication discontinuation, tailored treatment content, and empowerment.
conclusionsResults suggest digital CBT-I is well-accepted among cancer survivors. Digital CBT-I offers opportunities for treatment engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.